Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Zhao Peiqi, Shu Zhao, Chen Huang, Jiesong Wang, Junqing Xu, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Ying Chen, Yanan Jiang, Yanbin Zheng, Daoguang Chen, Yuhuan Gao, Qingyuan Zhang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2024-205438

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2024-201210

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2024-201190

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin

Blood (2023) 142 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2023-185363

Published: 2023

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Blood (2023) 142 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2023-182817

Published: 2023

Journal Articles

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2023-180485

Published: 2023

Journal Articles

CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL

Xiyue Xu, Qingpei Guan, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Yixin Yao, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 524.

https://doi.org/10.1182/blood-2023-188468

Published: 2023

Journal Articles

Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study

Jingwei Yu, Yaxiao Lu, Yixin Yao, Xianming Liu, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 3076.

https://doi.org/10.1182/blood-2023-188801

Published: 2023

Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2023-180694

Published: 2023

Journal Articles

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

Yuqin Song, Keshu Zhou, Lanfang Li, Aibin Liang, Yun Qin, Zhen Xia, Yongen Gu, Zisong Zhou, Alex Tian, Jun Zhu

Blood (2023) 142 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2023-178430

Published: 2023

Journal Articles

A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

Huilai Zhang, Liping Su, Lihong Liu, Ou Bai, Zheng Song, Zhiqiang Zhao, Cuiying He, Qiang Guo, Xianhuo Wang, Wei Li, Lihua Qiu, Lanfang Li, Shiyong Zhou, Yue Fei, Xiaohui Wang, Bin Meng

Blood (2023) 142 (Supplement 1): 736.

https://doi.org/10.1182/blood-2023-178509

Published: 2023

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao

Blood (2023) 142 (Supplement 1): 6928.

https://doi.org/10.1182/blood-2023-181351

Published: 2023

Journal Articles

PIM1 Genetic Alterations Associated with Distinct Molecular Profiles, Phenotypes and Drug Responses in Diffuse Large B-Cell Lymphoma

Xianhuo Wang, Yaxiao Lu, Sicong Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 9264–9265.

https://doi.org/10.1182/blood-2022-164976

Published: 2022

Journal Articles

Comprehensive Analysis of TP53 and CD58 Mutations and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma

Xianhuo Wang, Tingting Zhang, Yaxiao Lu, Yue Fei, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 9236–9237.

https://doi.org/10.1182/blood-2022-164603

Published: 2022

Journal Articles

Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China

Zhitao Ying, Keshu Zhou, Lanfang Li, Wenyu Li, Su Yang, Yun Liu, Yongen Gu, Zisong Zhou, Alex Tian, Yuqin Song, Jun Zhu

Blood (2022) 140 (Supplement 1): 7470–7471.

https://doi.org/10.1182/blood-2022-164525

Published: 2022

Journal Articles

Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL

Xianhuo Wang, Tingting Zhang, Hengqi Liu, Sicong Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 6458–6459.

https://doi.org/10.1182/blood-2022-165060

Published: 2022

NARROW

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL

Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL): Updated Results from a Phase II Open-Label Study in China

A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

PIM1 Genetic Alterations Associated with Distinct Molecular Profiles, Phenotypes and Drug Responses in Diffuse Large B-Cell Lymphoma

Comprehensive Analysis of TP53 and CD58 Mutations and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma

Preliminary Safety and Efficacy of Relmacabtagene Autoleucel (relma-cel) in Adults with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) in China

Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only